Abstract:Bridging nerve gaps by means of autologous nerve grafts involves donor nerve graft harvesting. Recent studies have focused on the use of alternative methods, and one of these is the use of biodegradable nerve guides. After serving their function, nerve guides should degrade to avoid a chronic foreign body reaction. The in vitro degradation, in vitro cytotoxicity, hemocompatibility, and short-term in vivo foreign body reaction of poly( 65 / 35 ( 85 / 15 L / D ) lactide-⑀-caprolactone) nerve guides was studied. The in vitro degradation characteristics of poly(DLLA-⑀-CL) nerve guides were monitored at 2-week time intervals during a period of 22 weeks. Weight loss, degree of swelling of the tube wall, mechanical strength, thermal properties, and the intrinsic viscosity of the nerve guides were determined. Cytotoxicity was studied by measuring the cell proliferation inhibition index (CPII) on mouse fibroblasts in vitro. Cell growth was evaluated by cell counting, while morphology was assessed by light microscopy. Hemocompatibility was evaluated using a thrombin generation assay and a complement convertase assay. The foreign body reaction against poly(DLLA-⑀-CL) nerve guides was investigated by examining toluidine blue stained sections. The in vitro degradation data showed that poly(DLLA-⑀-CL) nerve guides do not swell, maintain their mechanical strength and flexibility for a period of about 8 -10 weeks, and start to lose mass after about 10 weeks. Poly(DLLA-⑀-CL) nerve guides were classified as noncytotoxic, as cytotoxicity tests demonstrated that cell morphology was not affected (CPII 0%). The thrombin generation assay and complement convertase assay indicated that the material is highly hemocompatible. The foreign body reaction against the biomaterial was mild with a light priming of the immunesystem. The results presented in this study demonstrate that poly( 65 / 35 ( 85 / 15 L / D ) lactide-⑀-caprolactone) nerve guides are biocompatible, and show good in vitro degradation characteristics, making these biodegradable nerve guides promising candidates for bridging peripheral nerve defects up to several centimeters.
Biodegradable poly-(DL-lactide-co-glycolide) (PLGA) microspheres (MSP) are attractive candidate vehicles for site-specific or systemic sustained release of therapeutic compounds. This release may be altered by the host's foreign body reaction (FBR), which is dependent on the characteristics of the implant, e.g. chemistry, shape or size. In this study, we focused on the characterisation of the influence of MSP size on the FBR. To this end we injected monodisperse MSP of defined size (small 5.8 µm, coefficient of variance (CV) 14 % and large 29.8 µm, CV 4 %) and polydisperse MSP (average diameter 34.1 µm, CV 51 %) under the skin of rats. MSP implants were retrieved at day 7, 14 and 28 after transplantation. The FBR was studied in terms of macrophage infiltration, implant encapsulation, vascularisation and extracellular matrix deposition. Although PLGA MSP of all different sizes demonstrated excellent in vitro and in vivo biocompatibility, significant differences were found in the characteristics of the FBR. Small MSP were phagocytosed, while large MSP were not. Large MSP occasionally elicited giant cell formation, which was not observed after implantation of small MSP. Cellular and macrophage influx and collagen deposition were increased in small MSP implants compared to large MSP. We conclude that the MSP size influences the FBR and thus might influence clinical outcome when using MSP as a drug delivery device. We propose that a rational choice of MSP size can aid in optimising the therapeutic efficacy of microsphere-based therapies in vivo.
Vascular endothelial growth factor
(VEGF) is the major regulating
factor for the formation of new blood vessels, also known as angiogenesis.
VEGF is often incorporated in synthetic scaffolds to promote vascularization
and to enhance the survival of cells that have been seeded in these
devices. Such applications require sustained local delivery of VEGF
of around 4 weeks for stable blood vessel formation. Most delivery
systems for VEGF only provide short-term release for a couple of days,
followed by a release phase with very low VEGF release. We now have
developed VEGF-loaded polymeric microspheres that provide sustained
release of bioactive VEGF for 4 weeks. Blends of two swellable poly(ε-caprolactone)–poly(ethylene
glycol)–poly(ε-caprolactone)-
b
-poly(
l
-lactide) ([PCL–PEG–PCL]-
b
-[PLLA])-based
multiblock copolymers with different PEG content and PEG molecular
weight were used to prepare the microspheres. Loading of the microspheres
was established by a solvent evaporation-based membrane emulsification
method. The resulting VEGF-loaded microspheres had average sizes of
40–50 μm and a narrow size distribution. Optimized formulations
of a 50:50 blend of the two multiblock copolymers had an average VEGF
loading of 0.79 ± 0.09%, representing a high average VEGF loading
efficiency of 78 ± 16%. These microspheres released VEGF continuously
over 4 weeks in phosphate-buffered saline pH 7.4 at 37 °C. This
release profile was preserved after repeated and long-term storage
at −20 °C for up to 9 months, thereby demonstrating excellent
storage stability. VEGF release was governed by diffusion through
the water-filled polymer matrix, depending on PEG molecular weight
and PEG content of the polymers. The bioactivity of the released VEGF
was retained within the experimental error in the 4-week release window,
as demonstrated using a human umbilical vein endothelial cells proliferation
assay. Thus, the microspheres prepared in this study are suitable
for embedment in polymeric scaffolds with the aim of promoting their
functional vascularization.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.